The aim of this work was to identify micro-RNAs (miRNAs) involved in the pathological pathways activated in skeletal muscle damage and regeneration by both dystrophin absence and acute ischemia. Eleven miRNAs were deregulated both in MDX mice and in Duchenne muscular dystrophy patients (DMD signature). Therapeutic interventions ameliorating the mdx-phenotype rescued DMD-signature alterations. The significance of DMD-signature changes was characterized using a damage/regeneration mouse model of hind-limb ischemia and newborn mice. According to their expression, DMD-signature miRNAs were divided into 3 classes. 1) Regeneration miRNAs, miR-31, miR-34c, miR-206, miR-335, miR-449, and miR-494, which were induced in MDX mice and in DMD patients, but also in newborn mice and in newly formed myofibers during postischemic regeneration. Notably, miR-206, miR-34c, and miR-335 were up-regulated following myoblast differentiation in vitro. 2) Degenerative-miRNAs, miR-1, miR-29c, and miR-135a, that were down-modulated in MDX mice, in DMD patients, in the degenerative phase of the ischemia response, and in newborn mice. Their down-modulation was linked to myofiber loss and fibrosis. 3) Inflammatory miRNAs, miR-222 and miR-223, which were expressed in damaged muscle areas, and their expression correlated with the presence of infiltrating inflammatory cells. These findings show an important role of miRNAs in physiopathological pathways regulating muscle response to damage and regeneration.-Greco, S., De Simone, M., Colussi, C., Zaccagnini, G., Fasanaro, P., Pescatori, M., Cardani, R., Perbellini, R., Isaia, E., Sale, P., Meola, G., Capogrossi, M. C., Gaetano, C., Martelli, F. Common micro-RNA signature in skeletal muscle damage and regeneration induced by Duchenne muscular dystrophy and acute ischemia. FASEB J. 23, 000 -000 (2009). www.fasebj.org
Micro-RNAs (miRNAs) are noncoding RNA molecules that regulate the stability and/or the translational efficiency of target messenger RNAs. miRNAs have diverse functions, including the regulation of cellular differentiation, proliferation, and apoptosis (1) . Recent studies indicate that miRNA sequences can regulate skeletal and heart muscle function both in development and in disease, including cardiac hypertrophy and ischemia and muscular dystrophy (2) (3) (4) (5) .
Several miRNAs are specifically expressed or highly enriched in skeletal and/or cardiac muscle. Indeed, the expression of muscle-specific miR-1, miR-133, miR-206, and miR-208 is regulated by muscle transcriptional networks involving SRF, MyoD, Twist, MEF2, and myocardin (2) (3) (4) (5) . Interestingly, non-muscle-specific miRNAs, such as miR-26a and miR-181, also regulate skeletal muscle differentiation (6, 7) and regeneration after injury (7) .
Previous reports demonstrated miRNA deregulation in Duchenne muscular dystrophy (DMD) patients or in MDX mice, both lacking a functional dystrophin gene. Eisenberg et al. (8) described an miRNA expression profile in muscle tissues from several human primary muscle disorders and identified a series of miRNAs that are regulated either in almost all myopathies analyzed or specifically in DMD. Furthermore, the dysregulation of miR-206 has been described in MDX mice, a wellestablished mouse model of DMD (9, 10) . These pioneer studies indicate an important role of miRNAs in specific physiological pathways underpinning DMD pathology. However, they are necessarily far from saturating, and miRNA regulation in the complex cascade of events activated by dystrophin gene lesion still needs to be delineated.
In this study, miRNA expression was analyzed in muscles of both MDX mice and DMD patients, as well as in a mouse model of acute hind-limb ischemia. Their regulation by therapeutic interventions and by degenerative and regenerative events was investigated.
MATERIALS AND METHODS

Animal models and surgical procedures
All experimental procedures complied with the Guidelines of the Italian National Institute of Health and with the Guide for the Care and Use of Laboratory Animals (Institute of Laboratory Animal Resources, National Academy of Sciences, Bethesda, MD, USA) and were approved by the Istituto Dermopatico dell'Immacolata-Istituto Di Ricovero e Cura a Carattere Scientifico (IRCCS) (Rome, Italy) Institutional Animal Care and Use Committee. The following male 2-or 14-mo-old mice were used: MDX and their control C57BL/10 inbred mice, and 129 Sv-Ev p66
ShcA wild-type (wt) or knockout (ko) mice (11) . Before surgical procedures, mice were anesthetized with an intraperitoneal injection of 1 mg/kg medetomidine (Domitor; Vetem, Milan, Italy) and 75 mg/kg ketamine (Ketavet 100; Intervet Farmaceutici, Aprilia, Italy). Femoral artery dissection procedure (nϭ4/time point) was previously described (12) . Drug treatments: MDX mice received daily intraperitoneal injections of MS27-275 at a dose of 0.5 mg/kg or saline for 21 d (nϭ5/treatment) (13) . Gentamicin-treated MDX mice received subcutaneous injection of the drug (34 mg/kg/d) or saline for 3, 5, and 8 d (nϭ3/treatment) (14) .
Adenoviral transduction
Adductor muscles were infected with either adenoviruses CMV-GFP encoding the constitutively active allele of endothelial nitric oxide synthase (eNOS S1177D; nϭ3), or CMV-GFP-null (nϭ4). Muscles were injected with 1 ϫ 10 8 pfu/ animal of virus, according to previously published procedures (15) . For histological analysis, mice were perfused with phosphate-buffered saline (PBS) at various times after surgery, followed by 10% buffered formalin, at 100 mm/Hg for 15 min. Alternatively, mice were not perfused, and tissues were harvested for RNA extraction (12, 16) .
Human samples
All bioptic specimens were taken under institutionally approved protocols for diagnostic purposes after informed consent disclosing future use of the bioptic materials for research was obtained. If patients were minors, their parents were asked to sign the informed-consent form. DMD and myotonic dystrophy type2 (DM2) studies were reviewed and authorized by the institutional ethics committees of Catholic University Hospital (Rome, Italy) and IRCCS Policlinico San Donato, San Donato Milanese (Milan, Italy), respectively, and were conducted according to the institutional regulations and Italian laws and guidelines.
DMD diagnosis in patients was based on the absence of dystrophin immunoreactivity on quadriceps muscle sections. All patients were male (nϭ12, ageϭ1.6Ϯ1.2 yr). None of the patients was or had been under corticosteroid treatment at the time of biopsy. Control biopsies (nϭ10, ageϭ2.1Ϯ2.5 yr, difference vs. DMD not significant) were from males admitted with a suspected metabolic disorder that was not confirmed by histopathological and biochemical tests. Control biopsies did not show overt signs of muscle pathology on histological and histochemical examination. Both patients with DMD and control subjects were recruited at the Catholic University Hospital. DM2 diagnosis in patients was carried out by fluorescence in situ hybridization using (CAGG) 5 probes, as described previously (17) . Muscle biopsies were derived from biceps brachii in 9 patients (6 men, 3 women; mean age 52Ϯ4 yr). Control biopsies were from subjects (8 males and 6 females, age 46Ϯ3 yr, age and sex distribution differences vs. DM2 not significant) admitted with suspect myotonic dystrophy that was not confirmed by diagnostic tests. Control biopsies did not show overt signs of muscle pathology on histological and histochemical examination. Both patients with DM2 and control subjects were recruited at IRCCS Policlinico San Donato.
miRNA and mRNA quantification
Total RNA was extracted using TRIzol (Invitrogen, Carlsbad, CA, USA) and the TissueLyser system (Qiagen, Valencia, CA, USA). miRNA levels were analyzed using the TaqMan realtime PCR (qPCR) method (3.4 ng/assay), and quantified with a 7900HT Fast Real-Time PCR system (Applied Biosystems, Foster City, CA, USA). Primers for miRNAs and the reagents for reverse transcriptase and real-time PCR reactions were all obtained from Applied Biosystems. Relative expression was calculated using the comparative cycle threshold (Ct) method (2 Ϫ⌬⌬Ct ) (18) . Different samples were normalized to miR-16 expression. Conditions for miRNA profiling were previously described (19) . Briefly, 250 miRNAs were assayed in a 96-well format, and samples were normalized to the median Ct value. Heat maps were generated using Genesis 1.7.2 software (Graz University of Technology, Graz, Austria). mRNA levels were measured using the TaqMan RT-qPCR assay system (Applied Biosystems). Relative expression was calculated using the comparative Ct method. Different samples were normalized to GAPD expression.
Histology and laser-capture microdissection (LCM)
Hematoxylin-and-eosin (H&E)-stained sections were prepared as described previously (12) . Degenerating muscle fibers were identified by morphology, differential eosin staining, and presence of infiltrating cells near the degenerating fibers. Regenerating myofibers were identified by morphological criteria, central nucleus, and diameter Ͻ 30 m. A Zeiss Axioplan 2 fluorescence microscope with an image analyzer and KS300 software (Carl Zeiss, Oberkochen, Germany) was used to acquire images. All histological analyses were carried out by two masked readers with comparable results. LCM was performed as described previously (20) . Briefly, serial 10-m-thick sections were obtained from paraffinembedded adductor muscles and mounted on a polyethylene foil slide (Molecular Machines & Industries AG, Glattbrugg, Germany). Slides were stained with H&E, and normal, necrotic, or regenerating myofibers were dissected from serial tissue sections using an ultraviolet laser (SL-Microcut MMI Cellcut; Molecular Machines & Industries AG). The microdissected tissue areas were measured, documented, and collected on an adhesive cap of nanotubes (nϭ4 -6/cell type). RNA was extracted from dissected samples with miRNeasy FFPE Kit (Qiagen).
Single muscle fiber isolation
Single muscle fibers were isolated from collagenase-digested gastrocnemius, tibialis anterior, extensor digitorum longus, and soleus muscles (collectively indicated as tibialis muscles) of 6-wk-old mice (21) . Fibers were then withdrawn, washed twice, centrifuged at 500 rpm, and lysed with TRIzol within 2 h of the mouse sacrifice (nϭ4 -5).
Cell culture
C2C12 mouse myoblasts were cultured as described previously (nϭ6) (16) . To induce terminal differentiation, myoblasts were shifted to Dulbecco's modified Eagle's medium with 2% horse serum (differentiation medium, DM). To isolate human primary myoblasts, biceps brachii muscle biopsies (nϭ5) were trimmed of major blood vessels, fat, and connective tissues, minced and dissociated with trypsin. Cells were pelleted and plated in HAM's F10 medium (SigmaAldrich, St. Louis, MO, USA) supplemented with 15% FBS (Life Technologies, Inc., Gaithersburg, MD, USA), 0.5 mg/ml BSA (Sigma-Aldrich), 0.5 mg/ml fetuin, 0.39 g/ml dexamethasone, 10 ng/ml epidermal growth factor, 0.05 mg/ml insulin, 3 mg/ml glucose, 100 U/ml penicillin, and 100 g/ml streptomycin (growth medium, GM). To induce differentiation, 60% confluent myoblasts were switched to a DM consisting of DMEM supplemented with 7% FBS.
miRNA target prediction
Bioinformatic prediction of target genes and miRNA binding sites was performed using 2 different programs: TargetScan 4.2, April 2008 (22), and PicTar version 2006 (23) . For each miRNA, the predicted gene lists were confronted, and only common targets were used for a second comparison with the genes we previously found as dysregulated in pediatric patients with DMD (24) . Specifically, predicted targets of upregulated miRNAs were compared to the down-modulated genes and vice versa.
Statistical analysis
Variables were analyzed by both Student's t test and 1-way ANOVA, and a value of P Յ 0.05 was deemed statistically significant. Values are expressed as means Ϯ se.
RESULTS
Identification of a miRNA signature shared by MDX mice and DMD patients
To identify miRNAs involved in the pathological pathways activated by the dystrophin gene lesion, we compared the miRNA expression profile of adductor muscles derived either from MDX or wt mice. A panel of 250 miRNAs selected from the miRBase database was measured by real-time PCR, and the expression of 189 of them was detectable (Supplemental Table 1 ). Dystrophin deletion caused a dramatic change in the miRNA expression pattern (Supplemental Fig. S1 ), and the expression of 36 miRNA was affected significantly (Supplemental Fig. S2 ). miRNAs that were modulated Ͼ4 fold, either positively or negatively, were confirmed in a larger number of mice and selected for further analysis (Fig. 1) . miR-511 was not further examined, since it was barely detectable in mice of both genotypes. Conversely, miR-1 and miR-222 were included in this analysis, given their importance in regulating skeletal muscle differentiation and angiogenesis, respectively (25) . Among the regulated miRNAs, 8 were increased and 5 were down-modulated. In particular, miR-31 levels increased Ͼ70-fold (Fig. 1B) . Interestingly, while miR-206 and miR-1 exhibit a muscle-specific expression, the rest of the identified miRNA has been described in other tissues as well.
Since the MDX mouse model shares only certain features of DMD patients, we verified the expression of the identified miRNAs in skeletal muscle biopsies of DMD patients. It was found that, with the only exception of miR-124a and miR-516-3p, all miRNAs were deregulated in a similar manner in MDX mice and in DMD patients (Fig. 1 ). In keeping with the milder phenotype, Becker muscular dystrophy patients exhibited reduced miRNA expression modifications, and only miR-31 was up-regulated significantly (2.8Ϯ0.2, nϭ4, PϽ0.003). It has been shown that certain miRNAs are deregulated in different types of primary muscle disorders (8) . We assayed whether the same was true for the miRNA we identified in MDX mice and DMD patients. Figure 1 shows that none of the assayed miRNAs was significantly modulated in DM2 skeletal muscle biopsies, indicating the specificity of the identified DMD signature.
HDAC inhibition and nitric oxide rescue DMD-signature alteration
We previously reported that class I histone deacetylase inhibitors such as MS 27-275 are effective in the experimental therapy of mouse models of muscular dystrophy (24) . Moreover, we also demonstrated that both MS 27-275 and nitric oxide (NO) inhibited HDACs and ameliorated the mdx phenotype (13) . Thus, we investigated whether either HDAC inhibition or the restoration of NO signaling by a constitutively active endothelial NO synthase (eNOS) mutant, affected the expression of the DMD signature. MDX mice were injected intraperitoneally with MS 27-275 or saline and skeletal muscles were evaluated 3 wk later (13) . Alternatively, the adductor muscles of MDX mice were injected with either GFP-or eNOS-encoding adenoviruses, and miRNAs were measured 14 d postinfection. In keeping with previous observations (13, 26) , both treatments increased myofiber cross-sectional area and reduced both muscle fibrosis and cellular inflammatory infiltrate ( Fig. 2A) . We also observed that, with the exception of miR-223, the expression of the DMDsignature miRNAs returned to values similar to those observed in wt mice (Fig. 2B, C) .
Furthermore, the effect of the acute reexpression of dystrophin induced by gentamicin treatment for 3, 5, and 8 d was assayed. Longer treatments were not performed in order to avoid indirect effects, due to morphological and functional amelioration. We observed no significant changes in the expression of DMD-signature miRNAs compared to MDX mice treated with saline only (Supplemental Fig. S3 ).
DMD signature is modulated following ischemic damage and regeneration
Myofiber necrosis and regeneration are hallmarks of DMD, and are both present in MDX mice as well (27, 28) . To determine whether the observed alterations of miRNA expression were due to muscle fiber damage and/or to the consequent regenerative process, the hindlimb ischemia model was adopted. In this acute ischemia model, femoral artery removal induces a rapid increase of apoptosis and necrosis dispersed throughout the muscle, followed by a regeneration phase (Fig. 3A) (12, 16) . We also chose this experimental model because it represents a pathologically relevant model of tissue response to ischemia. Specifically, we used the 129 SvEv mouse strain, since in this mouse strain, the damage and the regenerative phases are temporally less overlapped compared to other strains, such as C57/BL10 (unpublished results). Figure 3B shows that miR-1 and miR-29c displayed a significant decrease at 2 d of ischemia, possibly because of the loss of skeletal myofibers and the induction of fibrosis (29) . miR-223 was strongly induced at 2 d as well, and then declined over time. MiR-206 expression followed a bimodal pattern, since it decreased at 2 d, again in correlation with the loss of myofibers, and peaked at 14 d, when skeletal muscle regeneration was strongly induced. Finally, miR-31, miR-34c, miR-222, miR-335, and miR-449 were induced over time and peaked at 14 d. MiR-135a and miR-494 were not significantly modulated. However, when the experiment was repeated in C57/BL10 mice that display faster kinetics of regeneration, miR-135a and miR-494 were significantly down-and up-regulated, respectively (Supplemental Fig. S4 ).
Contribution of different cell populations to DMD-signature modulation
We attempted to determine how single-myofiber subpopulations contributed to the observed modifications in the miRNA expression pattern. To this aim, hind- Common miRNA signature in MDX mice and in patients with DMD, but not in patients with DM2. A) Heat map representing miRNA modulated Ͼ4-fold (i.e., ⌬⌬CtϾ2.0) in MDX mice (nϭ7). These miRNAs were also measured in human quadriceps femoris biopsies derived from patients with DMD (nϭ12) or age-and sex-matched controls (nϭ10). The same miRNAs were measured in human biceps brachii biopsies of patients with DM2 (nϭ9) or age-and sex-matched controls (nϭ14). Average fold changes in MDX, DMD, and DM2 muscles were compared to relevant wt controls. Green and red indicate downand up-regulation, respectively; modulations are expressed using a log2 scale (Ϫ⌬⌬Ct). B) Table showing same values displayed in A in a linear scale. Significantly different values are in bold. *P Ͻ 0.05; **P Ͻ 0.01; ***P Ͻ 0.001.
limb ischemia was induced in 129 SvEv mice, and the LCM technique was used to isolate damaged, nondamaged, and regenerating myofibers from adductor muscle sections. It is worth noting that damaged areas contained not only necrotic and apoptotic myofibers, but also infiltrating inflammatory cells, as confirmed by histological sections and by the expression of the pan-leukocyte CD45 marker (Fig. 3A and data not  shown) . Given the limited amount of RNA yielded by LCM, only miRNAs displaying the strongest modulations were tested. As expected, miR-206 expression was low in damaged myofibers, it was not modulated in nondamaged myofibers either at 2 or 14 d after surgery, and it was strongly induced in regenerating myofibers (Fig. 4) ; miR-222 and miR-223 were strongly induced in damaged myofibers. However, because leukocytes are infiltrating these areas and miR-222 and miR-223 are strongly expressed in granulocytes (30, 31) , it is not possible to determine whether miR-222 and miR-223 increase was due to the ischemic stimulus per se or to the recruitment of inflammatory cells. When regenerating myofibers were analyzed, it was found that miR-31 and miR-34c exhibited very high induction levels (ϳ340-and 40-fold increase, respectively). MiR-335 was induced as well, albeit to a lower level.
To confirm these results, a different approach to isolate discrete cell populations within the ischemic muscle was used. Tibialis muscle cell components were disaggregated by protease treatment, and individual myofibers were isolated. Tibialis muscles were chosen for technical reasons. The absence of contaminating leukocytes was monitored by measuring CD45 expression. We found that while myofibers derived from 2-d ischemic muscles displayed CD45 expression, CD45 was undetectable in skeletal muscle fibers preparations derived from both 14-d ischemic and nonischemic muscles (not shown). Then, the expression of the DMD-signature miRNAs was compared in RNAs de- rived from either 14-d ischemic whole gastrocnemius or from purified myofibers. RNAs derived from 2-d ischemic muscles were used for reference as well. Figure 5 shows that, in keeping with results obtained with LCM, miR-31, miR-34c, miR-206, miR-335, and miR-449 were significantly up-regulated, both in whole gastrocnemius muscles and in isolated fibers. MiR-494 displayed a similar trend, albeit it did not reach statistical significance. MiR-222 and miR-223 were strongly induced in RNAs derived from 2-d ischemic whole muscles. At 14 d, in keeping with their lower induction in the ischemic whole gastrocnemius, miR-222 and miR-223
were not significantly modulated in the fibers as well. Finally, miR-1 and miR-29c were down-modulated in the ischemic whole gastrocnemius, but not in the isolated myofibers, indicating that the demise of miR-1 and miR-29c was not due to decreased expression levels in the myofibers and suggesting that their down-modulation was rather due to the loss of skeletal myofibers and to the induction of fibrosis.
We can conclude that the modulation of the DMDsignature miRNA is likely due to the continuous degenerative and regenerative processes and to the inflammation triggered by dystrophin deletion. Contribution of myofiber subpopulations to miRNA modulation following hind-limb ischemia. Hind-limb ischemia was induced, and histological sections of adductor muscles were derived at indicated times. LCM was used to isolate damaged, nondamaged, and regenerating and nonregenerating myofibers. Then, RNA was extracted, and the indicated miRNAs were measured. A) Heat map representing average miRNA modulations at different time points compared to myofibers of normoperfused muscles, expressed using a log2 scale (Ϫ⌬⌬Ct; nϭ4 -6). Green and red indicate down-and up-regulation, respectively. Damaged, necrotic and apoptotic myofibers containing inflammatory cells; regen., myofiber characterized by a central nucleus and diameter Ͻ30 m; no-regen., mature, apparently healthy myofibers. B) Table showing the same values displayed in A in a linear scale as miRNAs. Statistically significant differences are highlighted in bold. *P Ͻ 0.05; **P Ͻ 0.01; ***P Ͻ 0.001. Figure 5 . MiRNA modulation following hind-limb ischemia in isolated myofibers. Hind-limb ischemia was induced, and myofibers were isolated from collagenasedigested tibialis muscles. Single undamaged fibers were individually hand picked and washed twice in 1ϫ PBS. Then, RNA was extracted, and indicated miRNAs were measured. Absence of contaminating leukocytes was monitored by measuring CD45 expression. A) Heat map representing average miRNA modulations at different time points compared to myofibers of normoperfused muscles, expressed using a log2 scale (Ϫ⌬⌬Ct; nϭ4 -5/time point). Green and red indicate down-and up-regulation, respectively. Whole, whole gastrocnemius; fibers, isolated myofibers. B) Table showing the same values displayed in A in a linear scale as miRNAs. Statistically significant differences are in bold. *P Ͻ 0.05; **P Ͻ 0.01; ***P Ͻ 0.001.
miRNA decrease on ischemia correlates with skeletal muscle damage p66
ShcA -ko mice display decreased tissue damage and accelerated regeneration on hind-limb ischemia due to decreased oxidative stress levels (12, 16) . Thus, if miR-1, miR-29c, miR-135a, and miR-206 decrease following ischemia was due to the loss of skeletal myofibers and to the induction of fibrosis, one would expect an attenuation of these changes in p66
ShcA -ko mice. Hind-limb ischemia was induced in p66
ShcA -wt and -ko mice, and miR-1, miR-29c, miR-135a, and miR-206 levels were measured. Figure 6 shows that miR-1, miR29c, and miR-135a were not down-modulated at any time point. Conversely, they were up-regulated, albeit with different kinetics. Similarly, miR-206 was not significantly down-modulated at 2 d of ischemia, and its up-regulation was accelerated, in agreement with faster regeneration observed in these mice (16) .
Furthermore, we attempted to compare miRNA expression of young MDX mice with that of MDX mice at later stages of the disease, when regeneration is exhausted and degeneration and fibrosis occur (32) . To this aim, 14.5 Ϯ 0.5-mo-old mice were analyzed. Despite the advanced age, histological analysis clearly showed that abundant centrally nucleated regenerating myofibers, along with necrotic myofibers and infiltrating inflammatory cells, were still present in these mice (Supplemental Fig. S5A ). In keeping with these findings, DMD-signature dysregulation was reduced in older mice for certain miRNAs only (Supplemental Fig.  S5B ).
DMD signature is modulated in newborn muscle
DMD signature was regulated in concomitance with the regenerative process following ischemic damage. Thus, we assayed whether the DMD signature was, at least in part, modulated in the skeletal muscle of newborn mice. Indeed, unlike adult muscle, newborn skeletal muscle is characterized by intense growth in both cell number and volume. Figure 7 shows that, compared to adult muscle, miR-1 and miR-29c were down-modulated, while miR-31, miR-34c, miR-206, miR-335, miR-449, and miR-494 were up-regulated. As expected, given the absence of inflammation during physiological growth, miR-222 and miR-223 were not modulated.
Newborn MDX mice exhibit an apparently normal histological pattern, with tissue damage becoming apparent at later stages (32) . In keeping with these findings, when muscles derived from newborn MDX mice were analyzed, only marginal changes were observed compared to newborn wt mice (Fig. 7) .
miR-135a, miR-34c, and miR-335 are modulated on myogenic differentiation
Then, we tested whether DMD-signature miRNAs were, at least in part, modulated on myogenic differentiation in isolated cells. Figure 8 shows that miR-1, miR-135a, miR-34c, and miR-335, but not miR-31, increased on differentiation of C2C12 myoblast cell line. To confirm these results in human, nonimmortalized cells, myoblasts were isolated from biceps brachialis skeletal muscle biopsies of wt patients. Following culture in differentiation medium for 5 d, we observed that miR-1, miR-135a, miR-34c, and miR-335 were significantly induced.
These results indicate a cell-autonomous modulation of miR-1, miR-135a, miR-34c, and miR-335 during myogenic differentiation, further implicating these miRNAs in the skeletal muscle regenerative process. ShcA -ko mice. Femoral artery was removed from 129 SvEv p66 ShcA -ko mouse hind limb, and adductor muscles were taken at indicated times. Then, RNA was extracted, and miR-1, miR-29c, miR-135a, and miR-206 were measured. Bar graphs represent average fold changes; n ϭ 4. *P Ͻ 0.05; **P Ͻ 0.01.
Potential redundancy and reinforcement of the DMD-signature signaling
To gain insights into the biological pathways potentially regulated by DMD-signature miRNAs, we compared the genes we previously found as dysregulated in pediatric patients with DMD (32) to the predicted target genes of the DMD-signature miRNAs. Indeed, albeit the main effect of miRNAs is represented by translational repression, in many circumstances, miRNA binding to its Figure 7 . DMD signature is modulated in newborn mice. Hind-limb skeletal muscles were derived from 1-d-old wt and MDX mice, and expression of indicated miRNAs was compared to that of adult wt adductor muscles. A) Heat map representing miRNA modulations, expressed using a log2 scale (Ϫ⌬⌬Ct; nϭ4). Green and red indicate down-and up-regulation, respectively. B) Table showing the same values displayed in A in a linear scale. *P Ͻ 0.05; **P Ͻ 0.01; ***P Ͻ 0.001. Figure 8 . MiR modulation during myogenic differentiation of both human and mouse myoblasts. A) Representative cultures of human primary myoblasts. Cells were isolated from biceps brachialis skeletal muscle biopsies of wt patients, cultured in growth medium (GM) or in differentiation medium (DM) for 5 d, and stained using an antibody to MHC and Hoechst 33342. Scale bar ϭ 25 m. B) C2C12 cells and primary human myoblasts were cultured in GM and then shifted to DM for the indicated time for C2C12 and for 5 d for human myoblasts. Then, RNA was extracted, and indicated miRNAs were measured. Bar graphs represent expression average fold changes; n ϭ 5-6. **P Ͻ 0.01; ***P Ͻ 0.001. specific target triggers mRNA degradation (1) . To increase the stringency of our analysis, two prediction softwares were used, Pictar (23) and Targetscan (22) , and only common targets were considered for further analysis. More than 200 mRNA-miRNA potential interactions were identified (Supplemental Table 2 ). Intriguingly, redundancy between miRNAs displaying similar regulation was observed, leading to a potential reinforcement of the ensuing signaling. miR-34c and miR-449 on the one hand, and miR-1 and miR-206 on the other, had the same seed sequence and thus likely shared many targets. Moreover, certain genes were potential targets of more than one miRNA. For instance, CDK6 was targeted by miR-34c, miR-206, miR-449, and miR-494. Finally, dystrophin, which is substantially underexpressed in DMD muscle, was predicted to be a target of miR-31 and miR-499, according to Targetscan software.
DISCUSSION
Great efforts have been dedicated to the understanding of the mechanisms, both transcriptional and translational, leading to altered gene expression in dystrophic conditions. In this study, muscles derived from MDX mice were used to investigate muscle function regulated by miRNAs. Our approach was not intended to provide a comprehensive description of the disease, but it was aimed at the identification of an miRNA subset whose expression patterns might indicate a role in the pathological processes. To this aim, very stringent selection parameters were adopted in order to minimize the number of false positives. Indeed, we found that of 13 miRNAs identified in MDX mice, 11 were dysregulated in humans as well. MDX mice display several features of human DMD, but the disease is comparatively mild, possibly because of the partial compensatory role of utrophin (reviewed in ref. 32 ). Thus, it was not unexpected that miR-124a and miR-516-3p were not significantly modulated in humans. Further studies are needed to understand the functional implications of the observed differences and whether these miRNAs play any role in the disease attenuation observed in MDX mice. Finally, the identified DMD signature was specific as well, since none of the analyzed miRNAs was significantly modulated in DM2 patients.
Our study is in keeping with previous observations. Eisenberg et al. (8) identified miR-222, miR-335, and miR-29c as modulated in DMD, albeit a different profiling technique and older patients were used. Furthermore, our study confirms and greatly extends previous ones about miR-206 regulation in MDX mice (9, 10) .
Intriguingly, interventions targeting HDACs, either directly or reconstituting the NO signaling, rescued DMD-signature alteration, suggesting that the histological and functional improvement of the phenotype may dictate this molecular rescue. Thus, one may speculate that DMD-signature miRNAs may serve as useful markers for therapeutic purposes.
In keeping with this interpretation, no DMD-signature rescue was observed following acute dystrophin reexpression induced by short-time gentamicin treatment, before any morphological and functional effect could be appreciated. An important caveat, however, is represented by the fact that gentamicin treatment induces dystrophin amounts that are only 10 -20% of the wt (33) . These protein levels may be insufficient for a full rescue, and certain dystrophin-dependent pathways may be more sensitive than others.
The articulated series of experimental approaches adopted indicate that the DMD-signature miRNAs may be divided into three main classes: regeneration miRNAs, degenerative miRNAs, and inflammatory miRNAs. Regeneration miRNAs include miR-31, miR-34c, miR-206, miR-335, miR-449, and miR-494. These miRNAs were induced in MDX mice, in patients with DMD, in the regenerative phase of the hind-limb ischemia response, and in newborn mice. Mouse treatments that improved the MDX phenotype, thus reducing the number of regenerating myofibers, down-modulated their expression. When isolated regenerating myofibers, obtained either by LCM or by tissue disaggregation, were analyzed, these miRNAs were strongly upregulated. Finally, miR-206, miR-34c, and miR-335 were up-regulated following myoblast differentiation in vitro. Intriguingly, we found that miR-449 and miR-494 also were up-regulated in differentiating human myoblasts. However, we were unable to reproduce this observation in C2C12 cells (not shown).
Degenerative miRNAs miR-1, miR-29c, and miR-135a were down-modulated in MDX mice, in patients with DMD, in the degenerative phase of the hind-limb ischemia response, and in newborn mice. An intriguing possibility is that degenerative miRNAs may regulate, at least in part, critical mediators of cell death, contributing to the apoptotic/necrotic myofiber loss associated with both ischemia and DMD.
MiR-1 decrease is likely linked to the myofiber loss observed in dystrophin-deficient subjects and in the early phases of acute ischemia. Indeed, no decrease in miR-1 levels was observed when isolated fibers were analyzed or in p66 ShcA -ko mice that display decreased damage on ischemia and enhanced regeneration. In keeping with this interpretation, miR-206 was downmodulated at 2 d of ischemia as well, before its expression was activated during the regenerative phase of the response to ischemic damage. Finally, miR-1 decreased levels in newborn mice might be attributable to incomplete myofiber maturation. In a reciprocal manner, enhanced myogenic differentiation and regeneration observed in p66
ShcA -ko mice (16) correlated with increased miR-1 levels, at 14 and 21 d after ischemia.
miR-135a displays a regulation pattern similar to miR-1, and its expression is increased on myoblast differentiation in vitro and in p66
ShcA -ko mice exposed to ischemia. However, its minor regulation on acute ischemia in 129 SvEv-wt mice prevented its analysis in isolated fibers.
Another down-modulated miRNA is miR-29c. In-deed, other members of the miR-29-family (namely, miR-29a and miR-29b) were similarly decreased, albeit to a lower extent (Supplemental Fig. S2) . A recent article by Van Rooij et al. (29) shows that the miR-29 family of miRNAs are down-modulated in myocardial infarction, where they act as regulators of cardiac fibrosis. Thus, it is tempting to speculate that the miR-29 family may play a similar role in muscular dystrophy and in acute hind-limb ischemia. Indeed, when miR-29c was measured in p66 ShcA -ko mice that display lower levels of tissue damage and fibrosis in response to hind-limb ischemia (12, 16) , miR-29c was not down-modulated, but was actually increased in regenerating ischemic muscle. Similarly, MDX treatment with MS 27-275 or NO attenuated miR-29c decrease as well as fibrosis (13, 26) . However, a direct role in myogenesis of miR-29-family miRNAs cannot be excluded. Indeed, miR-29c was decreased in newborn mice, where fibrosis is unlikely to occur.
MiR-222 and miR-223 can be classified as inflammatory miRNAs. Indeed, they were highly expressed in damaged areas of the ischemic muscle, but not in nondamaged or regenerating tissue areas and in isolated fibers. Moreover, miR-223 is a key regulator of granulocyte function and is expressed at high levels in these cells (30, 31) . In keeping with these observations, miR-222 and miR-223 were not induced in muscles of newborn mice, both wt and MDX. Indeed, tissue degeneration first becomes apparent in MDX mice at 3-5 wk after birth (28) , and thus no substantial damage was present at the analyzed time. However, a more direct role of miR-222 cannot be ruled out, as it is downmodulated on in vitro differentiation of quail myoblasts (B. Cardinali and G. Falcone, Istituto di Biologia Cellulare, Consiglio Nazionale delle Ricerche, Rome, Italy; personal communication, January 6, 2008) .
While extensive studies are necessary to elucidate the role of each DMD-signature miRNA in tissue degeneration, regeneration, and inflammation, the analysis of the predicted target genes may provide useful indications. To this aim, we considered these targets that were predicted by both Pictar and Targetscan prediction algorithms and that further overlapped with genes we previously found as dysregulated in pediatric patients with DMD (24) . Despite the stringency of the adopted criteria, we identified more than 200 mRNA-miRNA potential interactions. Intriguingly, several mRNA were targeted by more than one miRNA within the same class or by both regeneration and inflammation miRNAs, indicating a potential reinforcement of the ensuing signal.
Intriguingly, we also observed that 5 miRNAs of the DMD signature were up-regulated on myogenic differentiation in vitro. While miR-1 and miR-206 induction in skeletal muscle differentiation was already known (2-5), miR-135a, miR-34c, and miR-335 up-regulation has not been described previously. Further studies will be necessary to determine the functional role of these miRNAs in the myogenic process and the molecular mechanisms underpinning their regulation.
In conclusion, the investigation of deregulated miRNAs in DMD and in response to ischemia is expected not only to broaden our biological understanding of these conditions, but even more importantly, to identify novel disease markers and potential targets for future clinical applications.
